o2h-ventures

NeoPhore is turning cold tumors hot by inhibiting DNA mismatch repair to produce more of the neoantigens that trigger immune attack.

Discovering drugs that create neoantigens
DNA Mismatch Repair Inhibitors
Clinicians see excellent immune responses for certain cancers that lack the mismatch repair ('MMR') genes targeted by NeoPhore’s approach
Status Active
Website https://www.neophore.com/
Category Biotech
Modality Small Molecule
Therapautics Area Oncology
Headquaters Cambridge, UK
Partner Phoremost
Investment Portfolio Pre-Fund Investment
Co-Investors Parkwalk Sixth Element